{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:32:45Z","timestamp":1794252765195,"version":"4.9.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To assess the predictive value of different chemical exchange saturation transfer (CEST) contrasts, i.e. of the amide proton transfer (APT), relayed nuclear Overhauser effect (rNOE), and semi-solid magnetization transfer (ssMT), as well as of clinical routine perfusion- and diffusion-weighted MRI, in terms of treatment outcome in patients with glioma following surgery at baseline before radiotherapy at 3 T.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      From September 2018 to December 2022, 78 study participants (median age 62 years, 27\/78 female) prospectively underwent CEST, diffusion, and perfusion imaging. CEST contrasts were reconstructed for the APT-weighted magnetization transfer ratio asymmetry (APTw\n                      <jats:sub>asym<\/jats:sub>\n                      ), relaxation-compensated CEST metrics (MTR\n                      <jats:sub>Rex<\/jats:sub>\n                      APT, MTR\n                      <jats:sub>Rex<\/jats:sub>\n                      NOE, MTR\n                      <jats:sub>Rex<\/jats:sub>\n                      MT), and MT\n                      <jats:sub>const<\/jats:sub>\n                      . Contrast-enhancing and whole tumor volumes were segmented on T2w-FLAIR and T1w images. Associations of mean contrast values with therapy response were tested using ROC analyses, while relationships with progression-free survival (PFS, median 6.04 months) and overall survival (OS, median 11.58 months), as well as added benefit compared to nCBV and ADC maps, were assessed using dichotomized Cox regression models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MTR\n                      <jats:sub>Rex<\/jats:sub>\n                      APT, MTR\n                      <jats:sub>Rex<\/jats:sub>\n                      NOE, and MTR\n                      <jats:sub>Rex<\/jats:sub>\n                      MT were associated with therapy response (AUC = 0.82, 0.81, 0.68; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.03), PFS (HR = 2.92, 0.37, 3.40; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.02), and OS (HR = 2.76, 0.63, 8.09; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.05). MT\n                      <jats:sub>const<\/jats:sub>\n                      was correlated with OS (HR = 5.52,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), while APTw\n                      <jats:sub>asym<\/jats:sub>\n                      was linked to therapy response (AUC = 0.71,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.02). MTR\n                      <jats:sub>Rex<\/jats:sub>\n                      MT (\u03c7\u00b2 = 13.71,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and MT\n                      <jats:sub>const<\/jats:sub>\n                      (\u03c7\u00b2 = 5.62,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.018) provided each additional value to nCBV for OS prediction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Relaxation-compensated CEST imaging of the APT, rNOE, and ssMT, as well as conventional APTw\n                      <jats:sub>asym<\/jats:sub>\n                      showed ability to predict treatment outcome, whilst ssMT-weighted imaging provided added benefit for OS prediction in patients with diffuse glioma following surgery at baseline before radiotherapy at 3 T.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-026-01022-y","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T09:23:26Z","timestamp":1774689806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of multimodal CEST, perfusion and diffusion MRI for predicting clinical outcome of patients with diffuse glioma following surgery at baseline before radiotherapy"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8453-3220","authenticated-orcid":false,"given":"Nikolaus","family":"von Knebel Doeberitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Menshchikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Gra\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora","family":"Bauspie\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Regnery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zeyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Schaumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Floca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bendszus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bachert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Ladd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Peter","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Korzowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Paech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"Supplement5","key":"1022_CR1","first-page":"v1","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neurooncology. 2022;24(Supplement5):v1\u201395.","journal-title":"Neurooncology"},{"issue":"3","key":"1022_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170\u201386.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1022_CR3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"9","key":"1022_CR4","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/ijc.34131","volume":"151","author":"K von Doeberitz","year":"2022","unstructured":"von Doeberitz K. Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas. Int J Cancer. 2022;151(9):1431\u201346.","journal-title":"Int J Cancer"},{"key":"1022_CR5","doi-asserted-by":"publisher","first-page":"810263","DOI":"10.3389\/fonc.2022.810263","volume":"12","author":"OM Henriksen","year":"2022","unstructured":"Henriksen OM, et al. High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques. Front Oncol. 2022;12:810263.","journal-title":"Front Oncol"},{"key":"1022_CR6","doi-asserted-by":"crossref","unstructured":"De Marco R, et al. A systematic review of amino acid PET imaging in adult-type high-grade glioma surgery: a neurosurgeon\u2019s perspective. Cancers (Basel). 2022;15(1).","DOI":"10.3390\/cancers15010090"},{"issue":"2","key":"1022_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40273-024-01447-y","volume":"43","author":"S van Mossel","year":"2025","unstructured":"van Mossel S, et al. A Systematic Literature Review of Modelling Approaches to Evaluate the Cost Effectiveness of PET\/CT for Therapy Response Monitoring in Oncology. PharmacoEconomics. 2025;43(2):133\u201351.","journal-title":"PharmacoEconomics"},{"key":"1022_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.neuroimage.2017.04.045","volume":"168","author":"PCM van Zijl","year":"2018","unstructured":"van Zijl PCM, et al. Magnetization Transfer Contrast and Chemical Exchange Saturation Transfer MRI. Features and analysis of the field-dependent saturation spectrum. NeuroImage. 2018;168:222\u201341.","journal-title":"NeuroImage"},{"key":"1022_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00117-020-00786-z","volume":"61","author":"K von Doeberitz","year":"2021","unstructured":"von Doeberitz K. Chemical exchange saturation transfer (CEST) Magnetic resonance imaging in diagnostic oncology. Radiologe. 2021;61:43\u201351.","journal-title":"Radiologe"},{"issue":"1","key":"1022_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40658-016-0155-2","volume":"3","author":"B Wu","year":"2016","unstructured":"Wu B, et al. An overview of CEST MRI for non-MR physicists. EJNMMI Phys. 2016;3(1):19.","journal-title":"EJNMMI Phys"},{"key":"1022_CR11","doi-asserted-by":"publisher","first-page":"1424316","DOI":"10.3389\/fnins.2024.1424316","volume":"18","author":"HZ Deng","year":"2024","unstructured":"Deng HZ, et al. Advances in diffuse glioma assessment: preoperative and postoperative applications of chemical exchange saturation transfer. Front Neurosci. 2024;18:1424316.","journal-title":"Front Neurosci"},{"key":"1022_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neuroimage.2015.02.040","volume":"112","author":"M Zaiss","year":"2015","unstructured":"Zaiss M, et al. Relaxation-compensated CEST-MRI of the human brain at 7T: Unbiased insight into NOE and amide signal changes in human glioblastoma. NeuroImage. 2015;112:180\u20138.","journal-title":"NeuroImage"},{"issue":"2","key":"1022_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/jmri.26645","volume":"50","author":"J Zhou","year":"2019","unstructured":"Zhou J, et al. APT-weighted MRI: Techniques, current neuro applications, and challenging issues. J Magn Reson Imaging. 2019;50(2):347\u201364.","journal-title":"J Magn Reson Imaging"},{"issue":"2","key":"1022_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/mrm.27751","volume":"82","author":"S Goerke","year":"2019","unstructured":"Goerke S, et al. Relaxation-compensated APT and rNOE CEST-MRI of human brain tumors at 3 T. Magn Reson Med. 2019;82(2):622\u201332.","journal-title":"Magn Reson Med"},{"issue":"3","key":"1022_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ijrobp.2018.03.057","volume":"101","author":"H Mehrabian","year":"2018","unstructured":"Mehrabian H, et al. Evaluation of Glioblastoma Response to Therapy With Chemical Exchange Saturation Transfer. Int J Radiat Oncol Biol Phys. 2018;101(3):713\u201323.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1022_CR16","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/mrm.29746","volume":"90","author":"F Kroh","year":"2023","unstructured":"Kroh F, et al. Semi-solid MT and APTw CEST-MRI predict clinical outcome of patients with glioma early after radiotherapy. Magn Reson Med. 2023;90(4):1569\u201381.","journal-title":"Magn Reson Med"},{"key":"1022_CR17","doi-asserted-by":"publisher","first-page":"109694","DOI":"10.1016\/j.radonc.2023.109694","volume":"184","author":"K von Doeberitz","year":"2023","unstructured":"von Doeberitz K. CEST imaging of the APT and ssMT predict the overall survival of patients with glioma at the first follow-up after completion of radiotherapy at 3T. Radiother Oncol. 2023;184:109694.","journal-title":"Radiother Oncol"},{"key":"1022_CR18","doi-asserted-by":"crossref","unstructured":"von Doeberitz K. N. Post-surgical depositions of blood products are no major confounder for the diagnostic and prognostic performance of CEST MRI in patients with glioma. Biomedicines. 2023;11(9).","DOI":"10.3390\/biomedicines11092348"},{"issue":"33","key":"1022_CR19","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, et al. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol. 2023;41(33):5187\u201399.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1022_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"1022_CR21","doi-asserted-by":"publisher","first-page":"e3879","DOI":"10.1002\/nbm.3879","volume":"31","author":"M Zaiss","year":"2018","unstructured":"Zaiss M, Ehses P, Scheffler K. Optimizing spiral-centric-reordered gradient echo acquisition for fast and robust 3D CEST MRI at 9.4 T. NMR Biomed. 2018;31(4):e3879.","journal-title":"NMR Biomed"},{"issue":"2","key":"1022_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/mrm.26133","volume":"77","author":"P Schuenke","year":"2017","unstructured":"Schuenke P, et al. Simultaneous mapping of water shift and B1 (WASABI)-Application to field-Inhomogeneity correction of CEST MRI data. Magn Reson Med. 2017;77(2):571\u201380.","journal-title":"Magn Reson Med"},{"issue":"11","key":"1022_CR23","doi-asserted-by":"publisher","first-page":"e4133","DOI":"10.1002\/nbm.4133","volume":"32","author":"J Breitling","year":"2019","unstructured":"Breitling J, et al. Adaptive denoising for chemical exchange saturation transfer MR imaging. NMR Biomed. 2019;32(11):e4133.","journal-title":"NMR Biomed"},{"issue":"2","key":"1022_CR24","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/mrm.29241","volume":"88","author":"J Zhou","year":"2022","unstructured":"Zhou J, et al. Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: Application to brain tumors. Magn Reson Med. 2022;88(2):546\u201374.","journal-title":"Magn Reson Med"},{"issue":"6","key":"1022_CR25","doi-asserted-by":"publisher","first-page":"E41","DOI":"10.3174\/ajnr.A4341","volume":"36","author":"K Welker","year":"2015","unstructured":"Welker K, et al. ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain. AJNR Am J Neuroradiol. 2015;36(6):E41\u201351.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"3","key":"1022_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00234-022-03072-y","volume":"65","author":"NS Cho","year":"2023","unstructured":"Cho NS, et al. A multi-reader comparison of normal-appearing white matter normalization techniques for perfusion and diffusion MRI in brain tumors. Neuroradiology. 2023;65(3):559\u201368.","journal-title":"Neuroradiology"},{"issue":"3","key":"1022_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.21037\/qims.2020.02.22","volume":"10","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, et al. Amide proton transfer-weighted magnetic resonance imaging of human brain aging at 3 Tesla. Quant Imaging Med Surg. 2020;10(3):727\u201342.","journal-title":"Quant Imaging Med Surg"},{"issue":"5","key":"1022_CR28","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3348\/kjr.2020.0700","volume":"22","author":"JH Oh","year":"2021","unstructured":"Oh JH, et al. Added Value of Chemical Exchange-Dependent Saturation Transfer MRI for the Diagnosis of Dementia. Korean J Radiol. 2021;22(5):770\u201381.","journal-title":"Korean J Radiol"},{"issue":"6","key":"1022_CR29","doi-asserted-by":"publisher","first-page":"e2318153","DOI":"10.1001\/jamanetworkopen.2023.18153","volume":"6","author":"S Fujita","year":"2023","unstructured":"Fujita S, et al. Characterization of Brain Volume Changes in Aging Individuals With Normal Cognition Using Serial Magnetic Resonance Imaging. JAMA Netw Open. 2023;6(6):e2318153.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1022_CR30","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1007\/s00330-019-06066-2","volume":"29","author":"D Paech","year":"2019","unstructured":"Paech D, et al. Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients. Eur Radiol. 2019;29(9):4957\u201367.","journal-title":"Eur Radiol"},{"issue":"47","key":"1022_CR31","doi-asserted-by":"publisher","first-page":"28772","DOI":"10.18632\/oncotarget.25594","volume":"9","author":"S Regnery","year":"2018","unstructured":"Regnery S, et al. Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. Oncotarget. 2018;9(47):28772\u201383.","journal-title":"Oncotarget"},{"issue":"12","key":"1022_CR32","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.1007\/s00330-019-06203-x","volume":"29","author":"B Joo","year":"2019","unstructured":"Joo B, et al. Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma. Eur Radiol. 2019;29(12):6643\u201352.","journal-title":"Eur Radiol"},{"key":"1022_CR33","doi-asserted-by":"crossref","unstructured":"Kroh F, et al. Semi-solid MT and APTw CEST-MRI predict clinical outcome of patients with glioma early after radiotherapy. Magn Reson Med. 2023.","DOI":"10.1002\/mrm.29746"},{"issue":"4","key":"1022_CR34","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/jmri.26900","volume":"51","author":"J Liu","year":"2020","unstructured":"Liu J, et al. Diagnostic performance of multiparametric MRI in the evaluation of treatment response in glioma patients at 3T. J Magn Reson Imaging. 2020;51(4):1154\u201361.","journal-title":"J Magn Reson Imaging"},{"issue":"12","key":"1022_CR35","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.1007\/s00330-016-4261-2","volume":"26","author":"KJ Park","year":"2016","unstructured":"Park KJ, et al. Added value of amide proton transfer imaging to conventional and perfusion MR imaging for evaluating the treatment response of newly diagnosed glioblastoma. Eur Radiol. 2016;26(12):4390\u2013403.","journal-title":"Eur Radiol"},{"issue":"3","key":"1022_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00234-020-02542-5","volume":"63","author":"YW Park","year":"2021","unstructured":"Park YW, et al. Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters. Neuroradiology. 2021;63(3):363\u201372.","journal-title":"Neuroradiology"},{"issue":"6","key":"1022_CR37","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/mrm.10651","volume":"50","author":"J Zhou","year":"2003","unstructured":"Zhou J, et al. Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med. 2003;50(6):1120\u20136.","journal-title":"Magn Reson Med"},{"issue":"12","key":"1022_CR38","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/neuonc\/noy073","volume":"20","author":"D Paech","year":"2018","unstructured":"Paech D, et al. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Neuro Oncol. 2018;20(12):1661\u201371.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1022_CR39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/mrm.28699","volume":"86","author":"S Goerke","year":"2021","unstructured":"Goerke S, et al. Clinical routine acquisition protocol for 3D relaxation-compensated APT and rNOE CEST-MRI of the human brain at 3T. Magn Reson Med. 2021;86(1):393\u2013404.","journal-title":"Magn Reson Med"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01022-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01022-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01022-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:03:37Z","timestamp":1781643817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01022-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1022"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01022-y","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of the Medical Faculty of Heidelberg University. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All enrolled participants gave consent for the publication of pseudonymized medical and imaging data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}